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Despite distinct etiological and clinical features, 
most chronic fibrotic disorders have in common 
a persistent irritant that sustains the production of 
growth factors, proteolytic enzymes, angiogenic 
factors,  and  fibrogenic  cytokines  (Wilson  and 
Wynn, 2009). Together, these factors stimulate 
the deposition of connective tissue elements that 
progressively remodel normal tissue architecture. 
Although  initially  beneficial,  tissue  repair  pro­
cesses become pathogenic when they are not 
regulated, resulting in substantial deposition of 
extracellular matrix (ECM) components and de­
velopment of scar tissue. In some diseases, like idio­
pathic pulmonary fibrosis (IPF), aberrant healing 
may lead to organ failure and death (Meltzer and 
Noble, 2008). Indeed, IPF and other chronic fi­
brotic lung diseases are associated with high mor­
bidity and mortality and are generally refractory 
to existing pharmacological therapy (Shah et al., 
2005). Therefore, better characterization of the 
molecular and immunological mechanisms of 
fibrosis is needed to identify new therapeutic 
modalities for these diseases.
Although a variety of cytokines, chemo­
kines, and growth factors are important regula­
tors of fibrosis, we identified a critical role for 
IL­13 in the development of fibrosis in schisto­
somiasis, a chronic liver disease caused by the par­
asitic helminth Schistosoma mansoni (Chiaramonte 
et al., 1999). Since then, IL­13 has been shown 
to exhibit fibrotic activity in a variety of diseases 
and tissues, including models of chronic asthma 
(Blease et al., 2001), skin fibrosis (Aliprantis et al., 
2007), and bronchiolitis obliterans (Keane et al., 
2007). A few recent studies have also suggested 
a role for IL­13 in bleomycin (BLM)­induced 
pulmonary fibrosis, a well­studied model of IPF 
(Jakubzick et al., 2003; Fichtner­Feigl et al., 
2006). It has been suggested that IL­13 triggers 
fibrosis by inducing and activating TGF­ (Lee 
et al., 2001). Nevertheless, the mechanism of ac­
tion of TGF­ in the development of pulmonary 
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Idiopathic pulmonary fibrosis (IPF) is a destructive inflammatory disease with limited thera-
peutic options. To better understand the inflammatory responses that precede and concur 
with collagen deposition, we used three models of pulmonary fibrosis and identify a critical 
mechanistic role for IL-17A. After exposure to bleomycin (BLM), but not Schistosoma 
mansoni eggs, IL-17A produced by CD4+ and + T cells induced significant neutrophilia 
and pulmonary fibrosis. Studies conducted with C57BL/6 il17a/ mice confirmed an essen-
tial role for IL-17A. Mechanistically, using ifn/, il10/, il10/il12p40/, and il10/ 
il17a/ mice and TGF- blockade, we demonstrate that IL-17A–driven fibrosis is sup-
pressed by IL-10 and facilitated by IFN- and IL-12/23p40. BLM-induced IL-17A produc-
tion was also TGF- dependent, and recombinant IL-17A–mediated fibrosis required 
TGF-, suggesting cooperative roles for IL-17A and TGF- in the development of fibrosis. 
Finally, we show that fibrosis induced by IL-1, which mimics BLM-induced fibrosis, is also 
highly dependent on IL-17A. IL-17A and IL-1 were also increased in the bronchoalveolar 
lavage fluid of patients with IPF. Together, these studies identify a critical role for IL-17A 
in fibrosis, illustrating the potential utility of targeting IL-17A in the treatment of drug 
and inflammation-induced fibrosis.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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the IL­13 decoy receptor (IL­13R2) was not significantly 
involved in the regulation of collagen deposition in the lung 
(Fig. 1, A and B). In contrast to S. mansoni egg–induced pul­
monary fibrosis, BLM­induced fibrosis appeared to be both 
IL­13 and IL­13R2 independent. Indeed, C57BL/6 WT, 
il13/, and il13R2/ mice all displayed indistinguishable 
levels of interstitial fibrosis after intratracheal delivery of BLM 
(Fig. 1, C and D).
BLM-induced pulmonary fibrosis is characterized by IFN- 
and IL-17A production
To elucidate the mechanisms involved in acute pulmonary 
inflammation and fibrosis after BLM administration, we char­
acterized the immune and pathological responses in mice over 
a 21­d period. Significant weight loss occurred during the first 
week after intratracheal BLM (Fig. 2 A). Marked increases in 
collagen deposition were also seen by day 7, with peak pulmo­
nary fibrosis developing between days 14 and 21 (Fig. 2, B, 
D, and F). Cachexia was associated with significant pneumonia 
and perivascular and peribronchial inflammation as early as day 
4 after BLM and persisting through day 21 (Fig. 2 D). The 
peak in fibrosis was preceded by marked increases in matrix 
metalloproteinase (MMP) 12, tissue inhibitor of MMP (TIMP) 
1 (Manoury et al., 2006), and COL­3 messenger RNA 
(mRNA) expression (Fig. 2 C), confirming activation of the 
collagen­producing machinery by BLM. Expression of IFN­, 
IL­13,  and  IL­17A  was  also  monitored  from  restimulated 
bronchoalveolar lavage (BAL) cells, lung leukocytes, and local 
draining LN cells (thoracic LN) to determine whether BLM­
induced fibrosis was associated with a Th1, Th2, and/or Th17­
type response. Marked increases in IFN­, followed by IL­17A, 
were detected between days 2 and 7 after BLM, whereas sig­
nificant increases in IL­13 were not observed before day 7. In 
fact, peak IL­13 production appeared to occur quite late when 
compared with IFN­ and IL­17A (Fig. 2 E). The kinetics of 
these three mediators suggested that BLM­induced inflamma­
tory and fibrotic responses are associated with a Th1/Th17 re­
sponse at early time points and a mixed Th1/Th17/Th2­type 
pattern at later times. As such, they illustrate that BLM triggers 
significant collagen deposition before the development of the 
Th2 response (Fig. 2, B and E), thus contrasting with the 
S. mansoni egg–induced fibrosis, which is highly dependent on 
IL­4 and IL­13 (Chiaramonte et al., 1999).
IL-10 limits IL-17A/IFN- production and pulmonary fibrosis
Exogenous IL­10 treatment suppresses BLM­induced fibrosis 
(Arai et al., 2000; Kitani et al., 2003; Kradin et al., 2004; 
Nakagome et al., 2006); however, the mechanism of action 
and role of endogenous IL­10 remains much less clear. Using 
IL­10gfp reporter mice, we identified the major source and 
pattern of expression of IL­10 after BLM challenge. IL­10 was 
detected in CD4+ and CD4 cells; however, the major in­
crease in IL­10 was observed in the CD4+ T cell population 
with minor increases in CD8+, CD19+, and CD11c+ cells 
(unpublished data). The percentage of CD4+ lymphocytes 
producing IL­10 increased within 2 d after administration of 
fibrosis remains controversial (Kaviratne et al., 2004; Varga 
and Pasche, 2008). Although it has been suggested that TGF­ 
contributes to BLM­induced inflammation and fibrosis by 
stimulating fibroblast proliferation and collagen­producing 
myofibroblasts (Cutroneo et al., 2007), recent studies also 
identified a critical role for TGF­ in the development of   
IL­17A–producing CD4+ T cells (Bettelli et al., 2006; Veldhoen 
et al., 2006), which regulate the pathogenesis of a variety of 
autoimmune and inflammatory diseases (Bettelli et al., 2008). 
Similarly, IL­1 can stimulate IL­17A production (Sutton 
et al., 2009), and IL­1 is a critical mediator of pulmonary 
fibrosis (Gasse et al., 2007). To date, however, a link between 
IL­17A–driven inflammation and pulmonary fibrosis has not 
been established.
The  aim  of  the  current  study  was  to  characterize  the 
mechanisms of pulmonary fibrosis and to determine whether 
IL­17A in particular plays an important regulatory role. To 
do this, three distinct model systems were used, including 
S. mansoni egg­induced pulmonary fibrosis, BLM­induced 
pulmonary fibrosis, and the recently described IL­1–driven 
fibrosis (Gasse et al., 2007). We report here that S. mansoni 
egg­mediated fibrosis is IL­13 dependent, as il13/ mice 
developed minimal fibrosis compared with WT mice. In 
marked contrast, BLM­induced pulmonary fibrosis was inde­
pendent of IL­13 at early time points. Instead, studies with 
il17a/ mice revealed a critical role for IL­17A. Using 
IL­10gfp reporter mice and newly generated IL­10 and IL­17A 
double cytokine­deficient animals, we determined that CD4+ 
cell­derived IL­10 is required to limit the production and 
frequency of IL­17A+CD4+ and IL­17A++ T cells, thus pre­
venting the development of severe IL­17A–driven fibrosis. 
We also show that IL­17A is essential for the development of 
fibrosis in response to IL­1, thus extending recent studies   
that described an early innate role for IL­1 in pulmonary   
fibrosis (Gasse et al., 2007). Together, these studies demon­
strate that fibrotic tissue remodeling is induced by distinct 
cytokine­dependent mechanisms, with the effector cytokines 
IL­13  and  IL­17A  playing  central  roles.  Moreover,  these 
findings suggest that TGF­ and proinflammatory mediators 
like IL­1 promote fibrosis by up­regulating the production 
of IL­17A, thus identifying IL­17A blockade as a potential 
treatment for fibrotic diseases like IPF.
RESULTS
Fibrosis is mediated by IL-13–dependent  
and IL-13–independent mechanisms
S. mansoni eggs delivered i.v. into S. mansoni egg–sensitized 
mice induce eosinophil­rich pulmonary granulomas around eggs 
trapped in the pulmonary microvasculature. The lesions are 
also associated with significant pulmonary fibrosis, as deter­
mined by hydroxyproline assay of lung tissue (Fig. 1 A). As ob­
served in the liver during S. mansoni infection (Chiaramonte   
et al., 1999), studies conducted with il13/ mice showed 
that pulmonary fibrosis is highly dependent on IL­13 (Fig. 1 A). 
However, unlike chronic liver fibrosis, hydroxyproline assays 
and Masson’s trichrome staining of lung tissue suggested that JEM VOL. 207, March 15, 2010 
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with pulmonary fibrotic diseases (Uebelhoer et al., 1993). 
These observations are also consistent with severe degradation 
of the basement membrane, enhanced alveolar permeability, 
and extensive lung injury in IL­10–deficient animals.
The exaggerated pathologies observed in il10/ mice 
were strongly correlated with increased production of IL­17A 
and IFN­ (Fig. 4 B). FACS analysis identified IFN­–
producing TCR+, CD8+, and CD4+ T cells in BLM­
challenged mice (Fig. 4 C), as well as CD3+ TCR+ IL­17A+ 
and CD3+ CD4+ IL­17A+ cells in the lungs 7 d after BLM 
treatment. A 10­fold increase in the percentage of CD4+ 
IL­17A+ cells was observed in il10/ mice (Fig. 4 C). In 
contrast, only a minor increase in the percentage of TCR+ 
IL­17A+ cells was noted. Nevertheless, a significant increase 
in the total number of both CD4+ and TCR+ populations 
in the lung (8.5­fold increase in CD4+ and 2.5­fold increase 
in TCR+) were observed in BLM­treatment of il10/ 
mice, suggesting that IL­10 regulates the development and 
influx of both CD4+ and TCR+ populations.
Analyses  of  whole  lung  homogenates  revealed  signifi­
cantly elevated levels of several IL­17A–promoting cytokines 
in BLM treated il10/ mice. These mediators included IL­6, 
IL­12/23p40, the neutrophil chemokine KC (CXCL1), and, 
perhaps most strikingly, IL­1, which was recently impli­
cated in BLM­induced fibrosis (Gasse et al., 2007) and in 
amplifying Th17 responses (Sutton et al., 2006, 2009; Fig. 4 D). 
BLM and remained elevated in the BAL and lung at all time 
points (Fig. 3 A). CD4+IL­10+ and CD4+IL­10 cells were 
FACS sorted from the lung of BLM­treated mice and ana­
lyzed  for  mRNA  transcripts.  IL­10  gene  transcripts  were 
highly up­regulated in CD4+IL­10+ sorted cells, confirming 
faithful reporter activity (Fig. 3 B). IL­17A mRNA tran­
scripts were also up­regulated in CD4+IL­10+ cells, suggest­
ing coexpression of IL­17A and IL­10, as previously reported 
(McGeachy et al., 2007; Stumhofer et al., 2007) and similar 
to IFN­ and IL­10 coexpressing cells (Anderson et al., 2007; 
Jankovic et al., 2007; Saraiva et al., 2009). Neither IFN­ 
and T­bet nor TGF­ and Foxp3 were coexpressed with 
IL­10, suggesting that IL­10–producing CD4 cells were not 
Th1 or Treg cells but, rather, were associated with IL­17A–
producing cells.
Germ line deletion of the il10 gene significantly acceler­
ated and increased pulmonary inflammation (Fig. S1, A and B), 
with the exacerbated response becoming most obvious by 
day 7. Histological scores of lung sections also revealed marked 
increases  in  perivascular  and  peribronchial  inflammation  in 
BLM­treated il10/ mice, as well as marked increases in pul­
monary fibrosis (Fig. S1 B). The increase in pulmonary fibrosis   
was also verified by quantitative measurements of lung hydroxy­
proline (Fig. 4 A). Marked increases in soluble collagen was 
also detected in the BAL of il10/ mice (Fig. 4 B), which 
was consistent with the increased levels observed in patients 
Figure 1.  IL-13–dependent and –independent pulmonary fibrosis. WT, il13/, or il13R2/ mice were given either 5,000 S. mansoni eggs i.p. fol-
lowed by 5,000 S. mansoni eggs i.v. 14 d later, with pulmonary fibrotic granulomas assessed 7 d later (d21; A and B), or an intratracheal delivery of 0.15 U 
BLM, with pulmonary fibrosis assessed on day 7 (C and D). One of two independent experiments is shown, with five animals per group. (A and C) Pulmo-
nary collagen deposition, expressed as micromoles of hydroxyproline per lung. Data shown are mean ± SEM. (B and D) 5-µm sections of paraffin-embedded 
lung tissue were stained with Masson’s Trichrome. Images are shown at 10× magnification. Collagen, blue; nuclei, dark red; cytoplasm, red/pink.  
Bars, 60 µm.538 IL-17A–mediated pulmonary fibrosis | Wilson et al.
is consistent with a recent study examining the in vitro dif­
ferentiation of human Th17 cells (Naundorf et al., 2009).
Neutrophilia is a common feature of pulmonary fibrosis 
(Hunninghake et al., 1981; Kinder et al., 2008), and IL­17A 
has been shown to be critically involved in the recruitment of 
IL­10 may, therefore, operate to regulate the development, 
in addition to the recruitment, of CD4+ and +IL­17A+ 
cells. In vitro Th17 cell differentiation was not directly influ­
enced by rIL­10 or anti–IL­10R treatment (Fig. S2), indicat­
ing that IL­10 does not directly influence Th17 cells, which 
Figure 2.  IL-17A and IFN- production during BLM-induced fibrosis. 0.15 U BLM was given to WT mice via intratracheal route, as in Fig. 1, with 
local immune profiling and assessment of tissue pathology analyzed from days 0 to 21, as indicated. One of three independent experiments is shown, 
with five animals per group. Data shown are mean ± SEM. (A) Weight loss, assessed at several time points after BLM, as indicated. (B) Pulmonary collagen 
score from histology sections. (C) RNA was extracted from lung tissue, with timp-1, mmp12, and pro–COL-3 mRNA quantified by quantitative RT-PCR.  
(D) 5-µm sections of paraffin-embedded lung tissue obtained from mice at the indicated day after BLM and stained with Masson’s Trichrome. Images are 
shown at a 5× magnification. Bars, 60 µm. (E) BAL, lung, and lung-draining thoracic LN (t:LN) cells were isolated and stimulated with anti-CD3 for 4 d. 
IL-17A, IFN-, and IL-13 were measured in culture supernatants by ELISA. (F) 5-µm sections of paraffin-embedded lung tissue obtained from mice at day 
7 after BLM stained with Giemsa or Picrosirius red (inset) shown under polarized light. Images are shown at 10× magnification. Bars, 60 µm.JEM VOL. 207, March 15, 2010 
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ing proinflammatory mediator release and the production of 
IL­17A from CD4+ and TCR+ cells.
IL-12/23p40 is required for IL-17A production  
and pulmonary fibrosis
IL­12/23p40 promotes the differentiation and expansion of 
both IL­17A and IFN­–producing lymphocytes. Given that 
all of these mediators were elevated in WT mice after BLM 
treatment, and to a greater extent in il10/ mice, we inves­
tigated whether IL­12/23p40 was regulating the develop­
ment of IL­17A–producing cells and pulmonary fibrosis. 
neutrophils to sites of inflammation via induction of CXC 
chemokines (Laan et al., 1999; Witowski et al., 2000; Miyamoto 
et al., 2003). Consistent with the marked IL­17A response, 
we detected a significant number of neutrophils in the lungs 
in BLM­treated mice. Indeed, a substantial increase in neu­
trophils was observed in both the lung and BAL (not de­
picted), as well as in the peripheral circulation (Fig. S1 B). 
The  neutrophil  response  was  also  exacerbated  in  il10/ 
mice, which was consistent with enhanced IL­17A responses 
(Fig. 4 B). Collectively, these data indicate that IL­10 limits 
lung injury, neutrophilia, and pulmonary fibrosis by suppress­
Figure 3.  IL-10–producing CD4 cells accumulate in the lung. 0.15 U BLM was given to C57BL/6 IL-10gfp mice via intratracheal route, as in Fig. 1. 
One of two independent experiments shown with five animals per group. Data shown are mean ± SEM. (A) Lung, BAL, or thoracic LN cells were isolated 
from IL-10gfp reporter mice and stained with anti–mouse CD3 and CD4. Horizontal bars show the mean. (B) CD4+IL-10gfp and CD4+IL-10gfp+ cells were 
FACS sorted (>98% pure) from the lung of BLM-treated mice at day 7. RNA was extracted and analyzed for mRNA transcripts. The dotted line refers to 
naive CD4+ cells.540 IL-17A–mediated pulmonary fibrosis | Wilson et al.
followed a similar pattern (Fig. 5 D). More importantly, how­
ever, we show that the exacerbated disease in il10/ mice 
was highly dependent on IL­12/23p40 production because 
il10/il12/23p40/  mice  were  almost  completely  pro­
tected from BLM­induced fibrosis (Fig. 5, B and C). We also 
extend  previous  studies  by  demonstrating  mechanistically 
that deletion of IL­12/23p40 is associated with reduced IFN­ 
production (Fig. 5 F) but markedly reduced expression of 
Using mice deficient in the p40 subunit of IL­12/23, we 
determined that IL­12/23p40 is critically involved in orches­
trating the lung inflammatory response after BLM administra­
tion (Fig. 5 A). The reduction in BLM­induced lung damage 
in p40/ mice was characterized by significantly decreased 
collagen in the BAL (Fig. 5 B) and lung (Fig. 5 C), which is 
consistent with related studies (Maeyama et al., 2001; Huaux 
et al., 2002; Sakamoto et al., 2002). Circulating neutrophilia 
Figure 4.  IL-10 restricts IL-17A and IFN- and the extent of pulmonary fibrosis. 0.15 U BLM was given to WT, IL-10gfp, or il10/ mice, via the 
intratracheal route, as in Fig. 1. *, P < 0.05 using a Mann-Whitney test. One of three independent experiments is shown with five animals per group. Data 
shown are mean ± SEM. (A) Pulmonary collagen deposition, expressed as micromoles of hydroxyproline per lung. (B) Thoracic LN cells were stimulated 
with anti-CD3, with IL-17A or IFN- measured in culture supernatants. BAL collagen was quantified from BAL fluid using Sircol assay. (C) Lung cells, 
isolated at day 7 after BLM, were stained with anti–mouse, CD4, CD8, B220, TCR, NK1.1, IL-17A, and IFN-, after a brief stimulation with PMA and 
ionomycin in the presence of BFA. The percentage of CD4+ or + cells producing IL-17A, in addition to the total number of cells recovered from the 
lungs, is enumerated in the table. (D) Homogenized lung supernatant was assayed by ELISA for the indicated cytokines/chemokines.JEM VOL. 207, March 15, 2010 
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ciated with decreased IL­17A expression (Fig. S3, B and E) 
and reduced circulating neutrophils (Fig. S3 A). Together, 
these data suggest that IFN­ may facilitate an IL­17A re­
sponse, as suggested in psoriatic lesions (Kryczek et al., 2008). 
This notion is also supported by an earlier induction of IFN­ 
in the lung compared with IL­17A (Fig. 2 E).
IL-17A is required for BLM-induced pulmonary fibrosis
To formally investigate the role of IL­17A in BLM­induced 
pulmonary fibrosis, WT and il17a/ mice were challenged 
with BLM. We also generated il10/il17a/ mice (double 
KO [dKO]) mice to determine whether the exacerbated lung 
IL­17A (Fig. 5 E). Our data, however, suggested a particu­
larly critical role for IL­17A because only IL­17A was signifi­
cantly  reduced  in  the  double  il10/il12/23p40/  mice 
(Fig. 5 F), correlating with markedly reduced disease (Fig. 5, 
A and B). Similar results were obtained by ELISA (Fig. 5, 
E and F) and by intracellular cytokine staining (Fig. 5 G). 
Nevertheless, previous studies identified an important role for 
IFN­ in BLM­induced fibrosis (Chen et al., 2001). Conse­
quently,  we  revisited  this  work  but  investigated  whether 
there was a possible mechanistic link between IFN­ and 
IL­17A.  Interestingly,  we  discovered  that  the  reduced  fi­
brotic response in ifn/ mice (Fig. S3, C and D) was asso­
Figure 5.  IL-12/23p40 deficiency significantly impacts IL-17A and IFN- and curtails pulmonary fibrosis. 0.15 U BLM was given to WT, il10/, 
il12/23p40/, or il10/il12/23p40/ mice via the intratracheal route as in Fig. 1. *, P < 0.05 using a Mann-Whitney test. One of two independent ex-
periments is shown, with five animals per group. Data shown are mean ± SEM. (A) 5-µm sections of paraffin-embedded lung tissue taken from WT or 
il10/ mice at day 7 or 21 after BLM and stained with Masson’s Trichrome. Images are shown at 5× magnification with dotted squares magnified at 40× 
in the insets. Bars: 60 µm; (inset) 7 µm. (B) Lung injury, measured as BAL collagen, was quantified from BAL fluid using Sircol assay. (C) Pulmonary col-
lagen deposition, expressed as micromoles of hydroxyproline per lung. (D) Absolute counts of circulating poly morphonuclear cells (PMNs) were obtained 
from CBC counts. (E and F) Thoracic LN cells were stimulated with anti-CD3, with IL-17A (E) and IFN- (F) measured in cultures supernatants. (G) Tho-
racic LN cells were stained with anti–mouse CD4, CD8, B220, TCR, NK1.1, IL-17A, and IFN- after a brief stimulation with PMA and ionomycin in the 
presence of BFA. Data shown is gated on CD4+ cells.542 IL-17A–mediated pulmonary fibrosis | Wilson et al.
as a dominant and critical mediator in the pathogenesis of 
BLM­induced pulmonary fibrosis.
IL-1–driven fibrosis is dependent on IL-17A
IL­1 mRNA expression (Fig. 6 F) and cytokine production 
(Fig. 4 D) correlated with the Th17 response and degree of fi­
brosis after BLM administration. Several recent studies have 
also identified an important role for IL­1 in the development 
of BLM­induced fibrosis. Indeed, administration of IL­1 
alone mimics much of the pulmonary pathology caused by 
BLM (Wang et al., 2000; Gasse et al., 2007; Ortiz et al., 2007; 
Hoshino et al., 2009). We confirmed and extended these 
observations by showing that intratracheal administration of 
IL­1 induces a marked IL­17A response (Fig. 7 C), as well as 
significant pulmonary fibrosis (Fig. 7, A and B). The adminis­
tration of 0.5 µg each of both IL­1 and IL­17A had a mild 
additive effect with increased collagen deposition and, most 
strikingly, increased MMP2 bioactivity (Fig. 7 D) compared 
with IL­1, IL­17A, or BLM treatment alone, suggesting in­
creased turnover of the ECM by IL­1 and IL­17A.
To test the requirement of IL­17A on IL­1–induced fi­
brosis, we administered IL­1 to either WT or il17a/ mice. 
As observed earlier, BLM­induced fibrosis was significantly 
reduced in il17a/ mice (Fig. 6), and, furthermore, IL­1–
mediated inflammation and fibrosis was also significantly re­
duced, almost to background levels, in the absence of IL­17A 
(Fig. 7, E and F). As observed with BLM, intratracheal IL­1 
induced significant neutrophilia (Fig. 7 G), TIMP­1 in the 
BAL (Fig. 7 H), and IFN­ and IL­17A production in the 
local  LNs  (Fig.  7  I).  IFN­  was  only  slightly  elevated  in   
the BAL after IL­1 treatment (Fig. 7 I). These mediators were 
all reduced in IL­1–treated il17a/ mice, indicating that 
IL­1–induced pulmonary disease, like BLM, is dependent 
on IL­17A for airway inflammation and pulmonary fibrosis.
IL-17A–dependent pulmonary fibrosis requires TGF-
Many studies have identified a profibrotic role for TGF­, 
particularly in the pathogenesis of pulmonary fibrosis (Cutroneo 
et al., 2007). More recently, studies have also suggested 
important inflammatory activities for TGF­, with TGF­ 
providing an integral differentiation signal for the develop­
ment of proinflammatory IL­17A–secreting cells (Bettelli 
et  al., 2006; Veldhoen et al., 2006). We therefore tested 
whether the profibrotic properties of TGF­ were linked to 
IL­17A. Intratracheal delivery of BLM or rIL­17A induced 
significant collagen release in the BAL (Fig. 8 A) and deposi­
tion in the lung (Fig. 8, B and D). TGF­ blockade signifi­
cantly reduced BLM and IL­17A–induced fibrosis (Fig. 8,   
B and D), identifying a critical requirement for TGF­ in 
both BLM and IL­17A–induced fibrosis. rIL­17A and BLM 
both increased IL­17A responses in the local LNs (Fig. 8 C), 
and TGF­ blockade curtailed endogenous IL­17A produc­
tion, indicating that TGF­ is required for the genesis of 
endogenous IL­17A. Together, these findings suggest coop­
erative and amplifying roles TGF­ and IL­17A in the devel­
opment of fibrosis.
fibrosis in IL­10–deficient animals was attributed to the en­
hanced Th17 response. IL­17A deficiency significantly reduced 
BLM­induced fibrosis in WT mice, as shown by analysis of 
collagen expression in the BAL (Fig. 6 A) and collagen depo­
sition in the lung (Fig. 6, B and E). The significant increase in 
IL­17A in il10/ mice (Fig. 4, B and C; and Fig. 6 H), 
which correlated with increased fibrosis, was also reduced 
to WT levels by deleting IL­17A (Fig. 6, A, B, and E).   
The reduction in fibrosis observed in il17a/ mice and 
il10/il17a/ mice also correlated with a similar decrease 
in circulating neutrophils (Fig. 6 C) and degree of weight loss 
(Fig. 6 D), further illustrating an important role for IL­17A 
in BLM­induced pathology and morbidity. The findings with 
il10/il12/23p40/ mice and il10/il17a/ dKO mice 
also point to IL­17A, rather than IFN­, as the critical down­
stream mediator of fibrosis because the il10/il12/23p40/ 
mice developed markedly reduced IL­17A and fibrotic re­
sponses yet maintained near normal IFN­ production. These 
observations also suggest that IL­10 inhibits the development 
of BLM­induced fibrosis by targeting the proinflammatory 
IL­23–IL­17A pathway rather than the IL­12–IFN­ axis.
Il17f, il22, and tnf were elevated in the lungs of BLM­
treated il10/ mice and remained elevated in il10/il17a/ 
mice, even though the dKO animals developed much less fi­
brosis (Fig. 6 F). Consequently, it seems unlikely that these 
Th17­associated mediators are contributing to the exagger­
ated fibrotic phenotype in il10/ mice. Interestingly, ifn 
mRNA (Fig. 6 F) and protein expression (Fig. 6 G) were sig­
nificantly reduced in il10/il17a/ mice compared with 
il10/ mice, suggesting that IL­17A may facilitate the recruit­
ment of IFN­–producing cells via lymphocyte­recruiting 
chemokines (Zrioual et al., 2008), cell survival (Sergejeva 
et al., 2005), or direct induction of IL­12 and IFN­ by mac­
rophages (Lin et al., 2009). It is interesting to note that 
IL­17A and IFN­ synergistically promote chemokine re­
sponses in a variety of inflamed tissues (Albanesi et al., 1999; 
Andoh et al., 2001; Eid et al., 2009), suggesting a coordinated 
response between IL­17A and IFN­.
In contrast to il17f, il22, and tnf, we observed a strong 
correlation between il1 expression and the degree of fibro­
sis in il10/ and il10/il17a/ mice. These observations 
were  revealing  because  IL­1  was  recently  implicated  in 
BLM­induced fibrosis in both humans and mice (Gasse et al., 
2007; Ortiz et al., 2007; Hoshino et al., 2009). il1 expres­
sion was also significantly reduced in il17a/ mice com­
pared with WT animals, suggesting that either IL­17A or 
IL­17A–dependent  responses  promotes  IL­1  production. 
IL­1 can indeed promote IL­17A responses (Sutton et al., 
2009); however, whether IL­17A directly or indirectly feeds 
back to enhance IL­1 has not been reported. Expression of 
several  ECM­associated  genes,  including  col3,  timp1,  and 
mmp12, was also reduced in il17a/ mice (Fig. 6 F). Further­
more, using zymography we observed reduced MMP­2 and 
MMP­9 activity in BAL fluid of il17a/ mice compared 
with WT and in il10/il17a/ mice compared with il10/ 
mice (Fig. 6 I). Collectively, these data clearly identify IL­17A JEM VOL. 207, March 15, 2010 
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Figure 6.  Attenuated pulmonary fibrosis in il17a/ mice. 0.15 U BLM was given to WT, il10/, il17a/, or il10/il17a/ mice, via the intratra-
cheal route, as in Fig. 1. *, P < 0.05 using a Mann-Whitney test. One of two independent experiments is shown, with five animals per group. Data shown 
are mean ± SEM. (A) Lung injury, measured as BAL collagen, was quantified from BAL fluid using Sircol assay. (B) Pulmonary collagen deposition, ex-
pressed as micromoles of hydroxyproline per lung. (C) Absolute counts of circulating polymorphonuclear cells were obtained from CBC counts. (D) Per-
centage of weight change, 7 d after BLM. (E) 5-µm sections of paraffin-embedded lung tissue taken from WT or il10/ mice at day 7 or 21 after BLM and 
stained with Masson’s Trichrome. Images are shown at a 40× magnification. Bar, 7 µm. (F) RNA was extracted from lung tissue, with indicated mRNA 
quantified by quantitative RT-PCR. (G and H) Thoracic LN cells were stimulated with anti-CD3, with IL-17A (G) and IFN- (H) measured in culture super-
natants. (I) MMP2 and MMP9 bioactivity measured in BAL by zymography.544 IL-17A–mediated pulmonary fibrosis | Wilson et al.
Figure 7.  IL-17A–dependent IL-1–induced collagen deposition. Mice were given intratracheal 0.15 U BLM, 1 µg IL-1, 1 µg IL-17A, or 0.5 µg 
each of both IL-1 and IL-17A with pulmonary collagen deposition assessed on day 7. *, P < 0.05 using a Mann-Whitney test. One of two independent 
experiments is shown, with five animals per group. Data shown are mean ± SEM. (A and E) 5-µm sections of paraffin-embedded lung tissue were stained 
with Masson’s Trichrome. Images are shown at a 20× magnification. Bars, 20 µm. (B and F) Pulmonary collagen deposition, expressed as micromoles of 
hydroxyproline per lung. (C and I) Thoracic LN cells were stimulated with anti-CD3, with IL-17A and IFN- measured in culture supernatants. (D) MMP2 
bioactivity in BAL fluid measured by zymography. (G) Absolute counts of circulating polymorphonuclear cells were obtained from CBC counts. (H) BAL 
fluid TIMP-1 and IFN- was measured by ELISA.JEM VOL. 207, March 15, 2010 
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IL-13–dependent pulmonary fibrosis is IL-17A independent
To determine whether IL­17A was functioning as a master reg­
ulator of fibrosis, we also exposed il17a/and il10/il17a/ 
mice to another model of pulmonary fibrosis. Previous stud­
ies have shown that S. mansoni egg–induced pulmonary fi­
brosis is highly dependent on IL­13 signaling (Ramalingam 
et al., 2008). However, IL­17A has been implicated in IL­13–
associated airway hyperreactivity (Nakae et al., 2002). The 
possible connection between IL­17A expression and Th2­
dependent fibrosis, however, has not been previously inves­
tigated (Wynn, 2008). We therefore assessed the impact of 
IL­17A on IL­13–dependant pulmonary fibrosis using the 
S. mansoni egg–induced pulmonary granuloma model. CD4+ 
IL­17A+ (1.1%), CD4+IFN­+ (13.1%), and CD4+IL­13+ 
(22.5%) lymphocytes were observed in WT mice 7 d after   
i.v. delivery of S.mansoni eggs to the lungs (Fig. 4 A), suggest­
ing a potential role for IL­17A in the development of fibrosis 
in this model. Deletion of il10 resulted in an approximate 
doubling of IL­17A–producing cells (1.1–2.5%) and a modest 
increase  in  IFN­–producing  cells  (13.1–16.3%).  Simi­
larly, when whole lung tissue was analyzed by quantitative 
RT­PCR,  significant  increases  in  il17a  and  ifn  mRNAs 
were observed, with only modest changes in il13 (Fig. S4, 
A and E). To test the importance of IL­17A in this model, 
WT, il17a/, il10/, and il10/il17a/ mice were chal­
lenged i.v. with S. mansoni eggs. In marked contrast to the BLM 
model (Fig. 6), BAL collagen (Fig. S4 B), hydroxyproline 
measurements (Fig. S4 C), and microscopic assessments of 
lung fibrosis (Fig. S4, D and G) revealed little to no role for 
IL­17A. Therefore, although IL­17A was significantly up­
regulated and increased further in the absence of IL­10 (Fig. S4, 
A and E), IL­13 appears to function as the dominant profi­
brotic mediator in this model. Production of IL­13 was not 
significantly affected by the presence or absence of IL­17A, 
suggesting no obvious regulatory role for IL­17A (Fig. S4, 
E and F). In fact little modulation of the ECM­related genes 
(mmp12, timp1, and col6a) was observed in the absence of 
IL­17A (Fig. S4 E). Moreover, although there was a modest 
increase in IFN­ in the IL­10–deficient groups, it had no 
significant impact on the development of IL­13–dependent 
fibrosis, perhaps because IL­13 was up­regulated 20­fold 
more than IFN­. Thus, in marked contrast to the BLM 
model, where IL­17A and, to a lesser extent, IFN­ appeared 
to play critical roles in the development of fibrosis, pulmo­
nary fibrosis induced by schistosome eggs appeared to be de­
pendent on Th2 cytokines. Thus, unique cytokine­dependent 
mechanisms can be exploited to induce pulmonary fibrosis, 
with IL­17A playing a critical role in BLM­induced fibrosis.
Increased IL-1 and IL-17A in BAL fluid of IPF patients
To determine whether IL­1 and IL­17A are involved in 
human IPF, we obtained lung biopsies and BAL fluid from 
normal volunteers (NVs) and IPF patients. Masson’s trichrome–
stained lung sections revealed inflammatory foci within the 
parenchyma, surrounded by dense collagen deposits (Fig. 9 B). 
Similar to the mouse model, IL­17A (NV, 1.48 ± 0.98 pg/ml; 
Figure 8.  IL-17A–dependent fibrosis requires TGF-. Mice were 
given 0.15 U of intratracheal BLM or 1 µg IL-17A with or without 500 µg 
of anti–TGF- treatment on days 1, 3, and 5. Pulmonary collagen depo-
sition was assessed on day 7. *, P < 0.05 using a Mann-Whitney test. One 
of two independent experiments is shown, with five animals per group. 
Data shown are mean ± SEM. (A) Lung injury, measured as BAL collagen, 
was quantified from BAL fluid using Sircol assay. (B) Pulmonary collagen 
deposition, expressed as micromoles of hydroxyproline per lung. (C) Tho-
racic LN cells were stimulated with anti-CD3, with IL-17A and IFN- mea-
sured in culture supernatants. (D) 5-µm sections of paraffin-embedded 
lung tissue were stained with Masson’s Trichrome. Images are shown at a 
20× magnification. Bars, 20 µm.546 IL-17A–mediated pulmonary fibrosis | Wilson et al.
illustrating the potential utility of targeting IL­17A in the 
treatment of IPF and other fibrotic diseases.
Previous studies have identified important roles for TGF­1 
and IL­13 in the development of fibrosis in a variety of tissues 
(Chiaramonte et al., 1999; Lee et al., 2001; Varga and Pasche, 
2008), whereas a role for IL­17A has remained unclear. Some 
studies found that IL­13 induces and activates TGF­1 (Lee 
et al., 2001), which then serves as the primary mediator of fi­
brosis by stimulating collagen synthesis in fibroblasts (Czaja 
et al., 1989). Nevertheless, other studies demonstrated that 
IL­13 could function independently of TGF­1 (Kaviratne 
et al., 2004). To better characterize both the unique and con­
vergent pathways of fibrosis, we dissected the mechanisms of 
pulmonary fibrosis in two distinct models in which TGF­1 
and IL­13 have been shown to function as critical mediators. 
Unexpectedly, although small interfering RNA gene silenc­
ing studies implicated IL­13 in the mechanism of BLM­
induced pulmonary fibrosis (Fichtner­Feigl et al., 2006), our 
studies conducted with C57BL/6 il13/ and il13R2/ 
mice failed to reveal a significant role for IL­13 signaling at 
this early stage of fibrosis in this model. In contrast, S. mansoni 
IPF, 14.31 ± 3.76 pg/ml) and IL­1 (NV, 9.58 ± 1.58 pg/ml; 
IPF, 21.36 ± 3.97 pg/ml), but not IL­22 (NV, 56.1 ± 2.00 
pg/ml; IPF, 50.7 ± 1.47 pg/ml; Whittington et al., 2004), in 
BAL fluid of IPF patients were increased (Fig. 9 A), indicting 
that an IL­1–IL­17A pathway may be involved in the de­
velopment of human IPF.
DISCUSSION
We have demonstrated that BLM­induced, but not S. mansoni 
egg–induced,  pulmonary  fibrosis  is  dependent  on  IL­17A 
produced by + and CD4++ T cells. In addition, we show 
that IL­17A is required for the development of inflammation, 
neutrophilia, and pulmonary fibrosis after exposure to IL­1, 
a recently described initiator of fibrosis (Wang et al., 2000; 
Ortiz et al., 2007; Gasse et al., 2007; Cassel et al., 2008; 
Hoshino et al., 2009). Mechanistically, using il10/, il10/ 
il17a/, and il10/il12p40/ dKO mice and TGF­ 
blockade, we also show that fibrosis is tightly controlled by 
IL­10–producing CD4+ lymphocytes, which regulate IL­17A 
production. Together, these studies identify IL­17A as a criti­
cal mediator of pulmonary fibrosis after BLM administration, 
Figure 9.  Elevated IL-17A and IL-1 in human IPF patient BAL fluid. BAL fluid and lung biopsies were collected from NVs and IPF patients. (A) BAL 
fluid was assayed for IL-17A and IL-1 by ELISA. (B) 5-µm lung sections were cut from paraffin-embedded lung biopsies and stained with Masson’s trichrome. 
Data shown are mean ± SEM. Images are shown at 5× (top) and dashed rectangles are magnified at 20× (bottom). Bars: (top) 60 µm; (bottom) 20 µm.JEM VOL. 207, March 15, 2010 
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position, magnifying the inflammatory cascade. One previous 
study suggested that IL­17A producing + T cells regulate 
cellular recruitment with + T cell–deficient mice develop­
ing increased inflammation and collagen deposition (Braun 
et al., 2008). These data suggest that + T cells may be het­
erogeneous and responsible for more than IL­17A, with pop­
ulations of + T cells providing a brake on the inflammatory 
response in addition to the early IL­17A production. A simi­
lar scenario could be envisioned for CD4+ T cells, providing 
both proinflammatory and fibrotic IL­17A in addition to 
antiinflammatory IL­10.
Several studies have identified an important regulatory 
role for IL­10 in BLM­induced pulmonary fibrosis (Kradin 
et al., 2004; Nakagome et al., 2006). These studies suggested 
that IL­10 controls BLM­induced inflammatory and fibrotic 
response by regulating chemokine and TGF­1 production 
(Kradin et al., 2004; Nakagome et al., 2006). However, we 
also found a marked increase in IL­17A in il10/ mice, 
which develop markedly exacerbated inflammation, neutro­
phil mobilization, and pulmonary fibrosis after BLM admin­
istration. These observations are consistent with studies 
that suggested IL­10 could regulate the magnitude and effec­
tor function of Th17 responses (Fitzgerald et al., 2007; 
McGeachy et al., 2007; Chang et al., 2008). Similar to previ­
ous studies (McGeachy et al., 2007; Stumhofer et al., 2007), 
IL­10 was often coexpressed with IL­17A and RoRt, sug­
gesting that Th17 cells may develop into IL­10–secreting 
cells to limit Th17 effector function.
To determine whether there was a functional connection 
between IL­10 and IL­17A, we generated il10/il17a/ 
dKO mice and then challenged the animals with BLM. Strik­
ingly, the increase in BLM­induced pulmonary fibrosis ob­
served in il10/ mice was completely reversed in the absence 
of IL­17A. As such, these studies explain the severe inflam­
matory response observed in il10/ mice (Kradin et al., 2004). 
They also identify IL­17A, which is produced predominantly 
by CD4+ T cells, as a critical target of IL­10. Gene transcripts 
for the IL­17A–related molecules IL­17F and IL­22 were 
also increased in the absence of IL­10, correlating with exag­
gerated inflammation and fibrosis (Fig. 6). However, these 
molecules were not largely affected in il17a/il10/ mice 
despite a significant reduction in pulmonary fibrosis, suggest­
ing that IL­17A, but not IL­17F or IL­22, functions as critical 
mediators  of  pulmonary  inflammation  and  fibrosis  at  this 
stage. Furthermore, IL­22 levels were not significantly different 
between control and pulmonary fibrosis patients (Whittington 
et al., 2004). A comprehensive study by Ishigame et al. (2009) 
highlighted the overlapping but also distinct roles of IL­17A 
and IL­17F. For example, IL­17A, but not IL­17F, was re­
quired for DTH, autoimmune encephalomyelitis, and collagen­
induced arthritis. However, IL­17A and IL­17F were both 
required  for  host  defense  against  Staphylococcus  aureus  and 
Citrobacter rodentium. Functionally, IL­17F and IL­17A also 
appear to have opposing roles in the allergic lung, with IL­17F 
negatively regulating and IL­17A positively regulating Th2­
mediated inflammation (Yang et al., 2008). From our data, it 
egg–induced pulmonary fibrosis was completely IL­13 de­
pendent. Together, these studies indicate that pulmonary 
remodeling and fibrosis can be induced by distinct nonover­
lapping mechanisms, with IL­13 functioning as the key driver 
of S. mansoni egg–driven fibrosis (Kaviratne et al., 2004) and 
IL­17A serving as a key mediator of BLM­induced fibrosis. 
The discovery that distinct immunological mechanisms can 
regulate fibrosis suggests that the etiology and/or route of the 
initial insult, as well as the character of the subsequent inflam­
matory response, may have a significant bearing on the na­
ture of the lung wound healing response. The distinct route 
of tissue damage observed in both models may contribute 
to the unique fibrotic mechanisms used. Indeed, S. mansoni 
eggs delivered i.v. primarily disrupt endothelial cells lining 
the pulmonary vasculature, whereas BLM administered intra­
tracheally is directly toxic to epithelial cells lining the air­
way. S. mansoni eggs are also highly immunogenic, inducing 
robust antigen­specific CD4+ Th2 responses (Everts et al., 
2009; Steinfelder et al., 2009), whereas BLM induces rapid 
epithelial cell death and destruction of DNA (Hay et al., 
1991), leading to acute proinflammatory Th1/Th17­type 
cytokine production.
Most studies of BLM­induced fibrosis have focused on 
the hypothesis that TGF­ regulates the development of pul­
monary fibrosis by directly promoting the differentiation and 
activation of collagen­producing myofibroblasts (Varga and 
Pasche, 2008). However, recent studies demonstrated that 
TGF­ is also critically involved in the development of 
IL­17A–producing lymphocytes (Bettelli et al., 2006; Veldhoen 
et al., 2006), which regulate the development of a variety of 
inflammatory and autoimmune diseases (Tesmer et al., 2008). 
Using il17a/ mice, we show that IL­17A is essential for the 
development of BLM­induced fibrosis. Similarly, blockade 
of TGF­ also significantly reduces BLM and IL­17A– 
induced fibrosis and correlates with reduced IL­17A produc­
tion. These findings suggest that the profibrotic activity of 
TGF­ may, at least in part, be attributed to the induction of 
IL­17A. Therefore, by stimulating myofibroblast activa­
tion and the production of IL­17A by T cells, TGF­ likely 
promotes BLM­induced fibrosis through both direct and 
indirect mechanisms. In contrast, development of S. mansoni 
egg–induced pulmonary fibrosis was completely IL­17A 
independent. Therefore, IL­17A appears to induce fibrosis in 
models where TGF­, but not IL­13, has been shown to 
play critical roles. IL­17A can directly induce the collagenase 
MMP­1  (Cortez  et  al.,  2007)  and  progelatinase,  MMP­3 
(Beklen et al., 2007) from various fibroblasts, suggesting that 
IL­17A may facilitate tissue disruption, in addition to its abil­
ity to promote granulopoiesis (Schwarzenberger et al., 1998) 
and inflammation. To this end, many studies have identified 
the proinflammatory properties of IL­17A. In the context of 
inflammation and pulmonary fibrosis, IL­17A can stimulate 
IL­6, IL­8, and MCP­1 from bronchial epithelial cells (Laan 
et al., 2001) or fibroblasts (Hata et al., 2002; Mahanonda 
et al., 2008) and, as mentioned in the previous paragraph, is 
inducible by IL­1 and IL­23, placing IL­17A in a central 548 IL-17A–mediated pulmonary fibrosis | Wilson et al.
nificantly fewer neutrophils in the lung than their respective 
control groups. Finally, IL­17A and IL­1 were also detected 
in the BAL fluid of IPF patients. When viewed together, these 
observations make a compelling case for IL­17A in the patho­
genesis of pulmonary inflammation and fibrosis.
In conclusion, genetic deletion of IL­17A significantly at­
tenuated  lung  inflammation,  neutrophilia,  and  fibrosis  in­
duced by BLM treatment in both WT and IL­10–deficient 
mice. In contrast, IL­17A appeared to play little to no role in 
the development of IL­13–dependent fibrosis. As such, these 
data identify distinct nonoverlapping immunological roles for 
IL­13 and IL­17A in the development of fibrosis. They also 
suggest that the IL­17A pathway might provide a novel ther­
apeutic target for the treatment of pulmonary fibrosis, for 
which few therapeutic options currently exist.
MATERIALS AND METHODS
Animals.  Female  6–10­wk­old  C57BL/6  (WT),  il10/,  il12/23p40/, 
ifn/, il13/, il13R2/, il10/il12/23p40/, and OVA­specific OT­II 
[C57BL/6­Tg(TCR­ TCR­)] (all C57BL/6 background for ≥10 gener­
ations) were obtained from National Institute of Allergy and Infectious Disease 
(NIAID) animal facilities at Taconic. IL­10gfp reporter mice were provided by 
R. Flavell (Yale University, New Haven, CT; Kamanaka et al., 2006). il17a/ 
animals were generated and provided by Regeneron (Leppkes et al., 2009). 
il10/il17a/ animals were generated by crossing il10/ with il17a/, 
with gene expression and protein production confirmed by PCR and ELISA. 
All animals were housed under specific pathogen­free conditions at the Na­
tional Institutes of Health in an American Association for the Accreditation 
of Laboratory Animal Care–approved facility. The NIAID animal care and use 
committee approved all experimental procedures. A minimum of five mice 
per group were used in each experiment, unless indicated.
Human tissues. Paraffin­embedded lung sections and BAL fluid were ob­
tained from 14 NVs and 7 patients diagnosed with IPF. 5­µm lung sections 
were stained with Masson’s trichrome as described in Histopathology and fi­
brosis. Subjects were enrolled in protocols 99­HG­0056 and/or 04­HG­
0211, which were approved by the National Human Genome Research 
Institute Institutional Review Board. Written informed consent was ob­
tained from all subjects. Bronchoscopy with BAL was performed as previ­
ously described (Ren et al., 2007).
Reagents and cell culture. For in vitro cell culture, LN cells were iso­
lated, washed, and plated at 5 × 105 cells per well of a 96­well plate and 
stimulated with 1 µg/ml of anti­CD3 antibody (clone 2C11; eBioscience). 
For in vitro Th17 differentiation, OVA peptide323­328 (New England Pep­
tide) was used at the indicated concentration to differentiate FACS­purified 
naive CD4+CD62LhiCD44lo T cells from OT2 OVA Tg mice into Th17 
cells with 20 ng/ml rIL­6 (R&D Systems), 5 ng/ml recombinant human 
TGF­ (R&D Systems), 10 µg/ml of anti–IL­4 (11D11), and 10 µg/ml of 
anti–IFN­ (XMG1.1), in combination with irradiated splenocytes or 1 µg/
ml of anti­CD3 (eBioscience) and 10 µg/ml of anti­CD28 (Invitrogen). 
rIL­10 (R&D Systems) or anti–IL­10RAb (BioXell; clone 1B1.3a) were 
added to cultures at the indicated concentrations. Anti–TGF­ (BioXell; 
clone 1D11) was used at 0.5 mg/mouse on days 1, 3, and 5.
Complete blood count (CBC) analysis. EDTA­treated blood was pro­
cessed for automated counting using a Vista Analyzer (Siemens).
Pulmonary fibrosis models. For Schistosoma mansoni egg–induced pulmo­
nary fibrosis, mice were immunized with 5,000 S. mansoni eggs by i.p. injec­
tion. Tail vein injection of 5,000 eggs was given on day 14, with analysis 
of fibrotic granuloma development 7 d later on day 21. For BLM­induced 
pulmonary fibrosis, mice were anaesthetized with a xylazine and ketamine 
appears that IL­17A, and not IL­17F or IL­22, is the domi­
nant molecule involved in BLM and IL­1–mediated pulmo­
nary inflammation and fibrosis.
Previous studies identified a role for IFN­ in BLM­
induced fibrosis (Chen et al., 2001), which was consistent with 
our findings. Surprisingly, we found that IFN­ deficiency 
was associated with reduced IL­17A production, suggesting a 
link between IFN­ and IL­17A. BLM studies performed 
with il12p40/ and il10/il12p40/ dKO mice confirmed 
this association; however, they indicated that IL­17A was func­
tioning as the dominant inducer of fibrosis. Indeed, reduced 
BLM­induced fibrosis in il12/23p40/ mice was associated 
with a much greater decrease in IL­17A than IFN­. A simi­
lar pattern was observed in BLM­treated il10/il12p40/ 
dKO mice. il17a/ and il10/il17a/ dKO mice also de­
veloped relatively normal IFN­ responses, despite signifi­
cantly reduced fibrosis. IFN­ responses in the lungs precede 
IL­17A responses (Fig. 2 E), suggesting that the IL­12–IFN­ 
axis may be involved in the recruitment of IL­23–dependent 
IL­17A– producing cells into the lung, as previously re­
ported (Kryczek et al., 2008). Nevertheless, these findings 
strongly suggest that the IL­23–IL­17A axis, rather than the 
IL­12–IFN­ pathway, plays the dominant role in BLM­
induced fibrosis, although both mechanisms are clearly in­
volved and connected.
In addition to TGF­1 and IL­23 (Langrish et al., 2005), 
recent studies identified an important role for IL­1 in Th17 
responses (Sutton et al., 2006). Interestingly, a recent study 
showed that IL­1R signaling is involved in BLM­induced 
pulmonary fibrosis, with exogenous IL­1 treatment recapit­
ulating much of the lung pathology seen with BLM (Gasse 
et al., 2007). We confirmed and extended these observations 
by showing that IL­1–mediated inflammation and fibrosis is 
dependent on IL­17A. These findings suggest that IL­17A 
functions as a critical downstream mediator of fibrosis. Inter­
estingly, the reduced inflammation and fibrosis observed in 
BLM­treated il17a/ animals was associated with reduced 
IL­1 expression, suggesting that IL­17A promotes IL­1 
production, as has been observed in vitro with cultured fibro­
blasts (Beklen et al., 2007). These data suggest that IL­17A 
and IL­1 cross­regulate each other, thus providing an expla­
nation for their additive roles in BLM­induced fibrosis.
BLM­induced fibrosis is associated with significant neu­
trophil recruitment to the lung. Indeed neutrophilia is a com­
mon feature of fibrosis and pulmonary alveolitis in IPF patients 
(Hunninghake et al., 1981; Kinder et al., 2008), with airway 
neutrophilia identified as a predictor of early mortality in IPF 
(Kinder et al., 2008). Interestingly, it is now well appreciated 
that IL­17A is involved in the recruitment of neutrophils to 
sites of inflammation via induction of IL­8 and CXC chemo­
kines, including MIP­2 (Laan et al., 1999; Witowski et al., 
2000; Miyamoto et al., 2003; Lindén et al., 2005). Neverthe­
less, a direct link between IL­17A, neutrophilia, and IPF has 
not been previously investigated. In our study, we observed a 
strong correlation between IL­17A and neutrophil recruit­
ment, with il17a/ and il10/il17a/ mice displaying sig­JEM VOL. 207, March 15, 2010 
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[Ramalingam et al., 2008]) or designed using Primer Express software (ver­
sion 2.0; Applied Biosystems; timp1 sense, 5­GCAAAGAGCTTTCT­
CAAAGACC­3, and anti­sense, 5­AGGGATAGATAAACAGGGAAA­
CACT ­3; il17a sense, 5­TGTGAAGGTCAACCTCAAAGTC­3, and 
anti­sense,  5­AGGGATATCTATCAGGGTCTTCATT­3;  il17f  sense, 
5­TGCTACTGTTGATGTTGGGAC­3, and anti­sense, 5­AATGCC­
CTGGTTTTGGTTGAA­3; il22 sense, 5­GTGAGAAGCTAACGTC­
CATC­3, and anti­sense, 5­GTCTACCTCTGGTCTCATGG­3; and 
il1 sense, 5­AAGGAGAACCAAGCAACGACAAAA­3, and anti­sense, 
5­TGGGGAACTCTGCAGACTCAAACT­3).
Zymography. 15 µl BAL fluid was mixed with an equal volume of Tris­
Glycine SDS sample buffer (Invitrogen) and subjected to electrophoresis 
with 10% gelatin zymogram gels (Invitrogen). According to manufacturer’s 
instructions, the gels were renatured, incubated in a developing buffer for 
24 h at 37°C, and stained with Simply Blue Safe Stain (Invitrogen). Pro and 
active forms of MMP2 and MMP9 were detected using protein molecular 
weight standards (Bio­Rad Laboratories) and MMP standards (EMD).
Statistical analysis. Datasets were compared by a Mann Whitney test or 
one­way analysis of variance, as specified in the figure legends, using Prism 
software v5. Differences were considered significant (*) at P < 0.05.
Online supplemental material. Fig. S1 demonstrates increased pulmonary 
inflammation and circulating neutrophilia in BLM­treated il10/ mice, com­
pared with BLM­treated WT mice. Fig. S2 shows that neither recombinant 
IL­10 nor anti–IL­10R blockade has a direct impact on Th17 cell generation 
in vitro. Fig. S3 corroborates other studies and demonstrates, using ifn/ 
mice, that IFN­ contributes to BLM­induced pulmonary inflammation and 
fibrosis. Fig. S4 shows that IL­17A is not required for S. mansoni egg–induced 
pulmonary inflammation and fibrosis. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20092121/DC1.
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